Overview


According to FutureWise analysis the market for cell and gene therapy manufacturing services in 2023 is US$ 6 billion, and is expected to reach US$ 22.14 billion by 2031 at a CAGR of 17.70%.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Cell and Gene Therapy Manufacturing Services Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Cell and Gene Therapy Manufacturing Services Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Thermo Fisher Scientific, Inc.
  • Merck KGaA
  • Charles River Laboratories
  • Lonza
  • Catalent, Inc.
  • WuXi AppTec
  • Takara Bio Inc
  • Nikon Corporation
  • Fujifilm Holdings Corporation
  • F. Hoffmann-La Roche Ltd.
  • Oxford Biomedica plc
  • Cell and Gene Therapy Catapult
  • The Discovery Labs LLC
  • RoslinCT
  • Jrs Pharma
  • FinVector
  • ABL, Inc.
  • Resilience
  • BioCentriq
  • Porton Biopharma Limited
  • Andelyn Biosciences
  • Commercializing Living Therapies
  • Vibalogics
  • Anemocyte Srl
  • ElevateBio

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Type

  • Cell Therapy
    • Allogeneic
    • Mesenchymal Stem Cells
    • T-cells
    • Induced Pluripotent Stem Cells
    • Natural Killer Cells
    • Hematopoietic Stem Cells
    • Other Allogeneic Cells
    • Autologous
    • T-cells
    • Hematopoietic Stem Cells
    • Mesenchymal Stem Cells
    • Natural Killer Cells
    • Viral Vector
    • Retroviral Vectors
    • Adeno-associated Virus Vectors
    • Other Viral Vectors
  • Gene Therapy
    • Non-viral Vector
    • Oligonucleotides
    • Other Non-viral Vectors
    • Viral Vector
    • Retroviral Vectors
    • Adeno-associated Virus Vectors
    • Other Viral Vectors

By Indication

  • Oncology Diseases
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Ophthalmology Diseases
  • Central Nervous System Disorders
  • Infectious Diseases
  • Other Indications

By Application

  • Clinical Manufacturing
  • Commercial Manufacturing

By End User

  • Pharmaceutical and Biotechnology Companies
  • Academic and Research Institutes
  • Other End Users

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa
  • Tier 1 players-established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the Cell and Gene Therapy Manufacturing Services Market By Type, By Indication, By Application, By End User and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions—North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping-product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Cell and Gene Therapy Manufacturing Services Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Cell and Gene Therapy Manufacturing Services Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Cell and Gene Therapy Manufacturing Services Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Cell and Gene Therapy Manufacturing Services Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Cell Therapy
         1.1. Allogeneic
          1.1.1. Mesenchymal Stem Cells
          1.1.2. T-cells
          1.1.3. Induced Pluripotent Stem Cells
          1.1.4. Natural Killer Cells
          1.1.5. Hematopoietic Stem Cells
          1.1.6. Other Allogeneic Cells
         1.2. Autologous
          1.2.1. T-cells
          1.2.2. Hematopoietic Stem Cells
          1.2.3. Mesenchymal Stem Cells
          1.2.4. Natural Killer Cells
         1.3. Viral Vector
          1.3.1. Retroviral Vectors
          1.3.2. Adeno-associated Virus Vectors
          1.3.3. Other Viral Vectors
        2. Gene Therapy
         2.1. Non-viral Vector
         2.2. Oligonucleotides
          2.2.1. Other Non-viral Vectors
         2.3. Viral Vector
          2.3.1. Retroviral Vectors
          2.3.2. Adeno-associated Virus Vectors
          2.3.3. Other Viral Vectors

  • 8.   Global Cell and Gene Therapy Manufacturing Services Market, By Indication Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oncology Diseases
        2. Cardiovascular Diseases
        3. Orthopedic Diseases
        4. Ophthalmology Diseases
        5. Central Nervous System Disorders
        6. Infectious Diseases
        7. Other Indications

  • 9.   Global Cell and Gene Therapy Manufacturing Services Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Clinical Manufacturing
        2. Commercial Manufacturing

  • 10.   Global Cell and Gene Therapy Manufacturing Services Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Pharmaceutical & Biotechnology Companies
        2. Academic & Research Institutes
        3. Other End Users

  • 11.   North America Cell and Gene Therapy Manufacturing Services Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Cell and Gene Therapy Manufacturing Services Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Cell and Gene Therapy Manufacturing Services Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Cell and Gene Therapy Manufacturing Services Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Thermo Fisher Scientific, Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Merck KGaA
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Charles River Laboratories
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Lonza
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Catalent, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. WuXi AppTec
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Takara Bio Inc
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Nikon Corporation
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Fujifilm Holdings Corporation
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. F. Hoffmann-La Roche Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Oxford Biomedica plc
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Cell and Gene Therapy Catapult
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. The Discovery Labs LLC
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. RoslinCT
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Jrs Pharma
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. FinVector
         16.1. Company Overview
         16.2. Product Portfolio
         16.3. SWOT Analysis
         16.4. Financial Overview
         16.5. Strategic Overview
        17. ABL, Inc.
         17.1. Company Overview
         17.2. Product Portfolio
         17.3. SWOT Analysis
         17.4. Financial Overview
         17.5. Strategic Overview
        18. Resilience
         18.1. Company Overview
         18.2. Product Portfolio
         18.3. SWOT Analysis
         18.4. Financial Overview
         18.5. Strategic Overview
        19. BioCentriq
         19.1. Company Overview
         19.2. Product Portfolio
         19.3. SWOT Analysis
         19.4. Financial Overview
         19.5. Strategic Overview
        20. Porton Biopharma Limited
         20.1. Company Overview
         20.2. Product Portfolio
         20.3. SWOT Analysis
         20.4. Financial Overview
         20.5. Strategic Overview
        21. Andelyn Biosciences
         21.1. Company Overview
         21.2. Product Portfolio
         21.3. SWOT Analysis
         21.4. Financial Overview
         21.5. Strategic Overview
        22. Commercializing Living Therapies
         22.1. Company Overview
         22.2. Product Portfolio
         22.3. SWOT Analysis
         22.4. Financial Overview
         22.5. Strategic Overview
        23. Vibalogics
         23.1. Company Overview
         23.2. Product Portfolio
         23.3. SWOT Analysis
         23.4. Financial Overview
         23.5. Strategic Overview
        24. Anemocyte Srl
         24.1. Company Overview
         24.2. Product Portfolio
         24.3. SWOT Analysis
         24.4. Financial Overview
         24.5. Strategic Overview
        25. ElevateBio
         25.1. Company Overview
         25.2. Product Portfolio
         25.3. SWOT Analysis
         25.4. Financial Overview
         25.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
                  administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients